The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study.
 
Manali A. Bhave
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Merck; Pfizer
 
Komal L. Jhaveri
Consulting or Advisory Role - Abbvie; AstraZeneca; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Gilead Sciences; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Sanofi; Scorpion Therapeutics; Seagen; Sun Pharma Advanced Research Company; Synthon; Taiho Oncology
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Clovis Oncology (Inst); Context Therapeutics (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Scorpion Therapeutics (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gilead Sciences; Intellisphere; Jounce Therapeutics; Lilly; Pfizer; Taiho Pharmaceutical
 
Peter A. Kaufman
Stock and Other Ownership Interests - Amgen; Johnson & Johnson/Janssen
Honoraria - AstraZeneca; Eisai; Lilly
Consulting or Advisory Role - AstraZeneca; Eisai; Lilly; Macrogenics; Merck; Pfizer; Polyphor; Roche/Genentech; Sanofi; Seagen; Sermonix Pharmaceuticals
Speakers' Bureau - Lilly
Research Funding - Eisai (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst); Sanofi (Inst); Sermonix Pharmaceuticals (Inst); Zymeworks (Inst)
Expert Testimony - Seagen
Travel, Accommodations, Expenses - Lilly; Polyphor; Seagen
 
Philippe Georges Aftimos
Honoraria - Gilead Sciences; Roche; Synthon
Consulting or Advisory Role - Amcure; Amgen; Boehringer Ingelheim; Deloitte; G1 Therapeutics; Gilead Sciences; Incyte; Lilly; Macrogenics; Menarini; Novartis; Novartis; Radius Health; Roche; Servier
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; MSD Oncology; Pfizer; Roche Belgium
 
Janine Margaret Lombard
Honoraria - AstraZeneca; Eisai; Gilead Sciences; GlaxoSmithKline; Novartis
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Lilly
 
Kostandinos Sideras
No Relationships to Disclose
 
Seock-Ah Im
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
 
Cynthia X. Ma
Consulting or Advisory Role - AstraZeneca; Biovica; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Genzyme; Gilead Sciences; Lilly; Novartis; Olaris; Pfizer; Regor Therapeutics Group; Stemline Therapeutics; Tempus; Tersera; Tersera
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate: Authorship - served as a co-author on the subject of endocrine therapy for metastatic breast cancer and receive compensation as an author, less than a few hundred dollars a year. It does not affect my patient care or research.
Travel, Accommodations, Expenses - SABCS; Total Health Conferencing
 
Kuo-Ting Lee
No Relationships to Disclose
 
Sung-Bae Kim
Stock and Other Ownership Interests - Genopeaks
Honoraria - DAEHWA Pharmaceutical; Kalbe Farma; LegoChem Biosciences
Consulting or Advisory Role - AstraZeneca; BeiGene; DAEHWA Pharmaceutical; Daiichi Sankyo/Astra Zeneca; Ensol Biosciences; ISU Abxis; Lilly (Inst); OBI Pharma
Research Funding - Genzyme (Inst)
 
Yujia Li
Employment - Lilly; Memorial Sloan-Kettering Cancer Center (I)
Stock and Other Ownership Interests - Illumina (I); Lilly; Lilly (I); Pfizer (I)
Travel, Accommodations, Expenses - Lilly
 
Eunice Yuen
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Shawn T. Estrem
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Bastien Nguyen
Employment - Loxo/Lilly
 
Francesca Bacchion
Employment - Canfield Scientific (I); Lilly; Mérieux (I)
Stock and Other Ownership Interests - Lilly
 
Roohi Ismail-Khan
Employment - Eli Lilly/ Loxo Oncology
Stock and Other Ownership Interests - Lilly
 
Muralidhar Beeram
Honoraria - Genentech (Inst); Johnson & Johnson (Inst)
Consulting or Advisory Role - Bayer (I); Merck (I); Novartis (I); Seagen (I)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst)
Research Funding - Agios (Inst); AstraZeneca (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Phoenix Molecular Designs (Inst); Puma Biotechnology (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Genentech; Merck
 
Joohyuk Sohn
Stock and Other Ownership Interests - Daiichi Sankyo (I)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myerss guibb (Inst); Celcuity (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); Eikon (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hanmi Pharm (Inst); HLB Life Science (Inst); ILDONG PHARMACEUTICAL (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Olema Oncology (Inst); Pfizer (Inst); Qurient (Inst); Roche (Inst); Samyang Holdings (Inst); Sanofi (Inst); Seagan (Inst); Sermonix Pharmaceuticals (Inst)